Gilead's New HIV Treatment Shows Promise in Phase 3 Trials
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy GILD?
Source: Businesswire
- Clinical Trial Results: At CROI 2026, Gilead presented data from the ARTISTRY-1 and ARTISTRY-2 trials, demonstrating that the BIC/LEN single-tablet combination was non-inferior to complex multi-tablet regimens in maintaining HIV viral suppression, with 0.8% of participants on BIC/LEN having HIV-1 RNA ≥ 50 copies/mL at Week 48 compared to 1.1% on complex regimens, indicating the efficacy of the new treatment.
- Increased Patient Satisfaction: The switch to BIC/LEN significantly improved patient-reported treatment satisfaction, with an average increase of 7 points in the HIVTSQs score, highlighting the potential of the new regimen to enhance quality of life for patients who have relied on complex multi-tablet regimens for extended periods.
- Good Tolerability: BIC/LEN was generally well tolerated, with drug-related adverse events reported in 14.3% of participants switching to BIC/LEN compared to 1.6% in the complex regimen group, and similar rates of serious adverse events were observed, indicating no significant safety concerns with the new regimen.
- Improvement in Lipid Parameters: Switching to BIC/LEN was associated with a median change in total cholesterol of -15 mg/dL, compared to +2 mg/dL in the complex regimen group, demonstrating the new regimen's advantage in improving metabolic health, which may contribute to optimized long-term treatment outcomes.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GILD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GILD
Wall Street analysts forecast GILD stock price to fall
19 Analyst Rating
16 Buy
3 Hold
0 Sell
Strong Buy
Current: 150.030
Low
105.00
Averages
137.88
High
154.00
Current: 150.030
Low
105.00
Averages
137.88
High
154.00
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It has a cancer program, namely TREX1. It operates in more than 35 countries worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Gilead Executive Highlights Potential $20 Billion Market for Anti-Cel in First-Line Multiple Myeloma Treatment at TD Cowen Conference
Potential Financial Impact: Sanito-Cel could potentially add up to $20 billion in value through its multiple myeloma treatment options.
Focus on First-Line Treatment: The emphasis is on the use of Sanito-Cel in first-line treatment settings, highlighting its significance in addressing this type of cancer.
See More
Gilead Foundation Invests $12 Million to Strengthen HIV Prevention Efforts
- Investment Scale: Gilead Foundation announced a $12 million investment in 33 community organizations nationwide to support its Community Health Worker Comprehensive HIV Prevention Initiative, aiming to enhance the accessibility and effectiveness of HIV prevention services over the next two years.
- Community Impact: The initiative prioritizes communities most affected by HIV, including Black and Latino men, transgender women, and youth, aiming to reduce health disparities by providing tailored education and prevention services.
- Organizational Infrastructure: Funded organizations will strengthen training systems for community health workers and build sustainable HIV prevention networks, thereby enhancing community trust and engagement in health services.
- Long-term Vision: Gilead Sciences plans to invest $32 billion by 2025 to further strengthen its U.S. operations, driving public health preparedness and scientific innovation to ensure patients worldwide benefit from its medical breakthroughs.
See More
Gilead Executive Anticipates Anti-Cel Launch by Year-End at TD Cowen Conference
- Launch Announcement: The Sanito-Cel is expected to launch by the end of this year, as stated by Gilead executives.
- Event Context: This announcement was made during the TD Cowen conference, highlighting the company's strategic plans.
See More
Significant Milestones in Biotech Sector This Week
- FDA Drug Approvals: Armata Pharmaceuticals' AP-SA02 received FDA's QIDP designation, granting five years of market exclusivity and paving the way for a Phase 3 trial in 2026, which is expected to significantly enhance the company's competitive edge in the antibiotic market.
- Weight Loss Innovation: Allurion Technologies' gastric balloon system gained FDA approval, offering a non-surgical weight loss option for patients with a BMI of 30-40, which is anticipated to expand the company's market share in the obesity sector.
- Acquisition Deal: Gilead Sciences is acquiring Arcellx for $115 per share, totaling $7.8 billion, a move that will strengthen Gilead's position in cell therapy and enhance its collaboration with Kite Pharma.
- Clinical Trial Developments: Novo Nordisk's CagriSema missed key goals in its trial against Zepbound, although it demonstrated a favorable safety profile, which may influence future market strategies.
See More
Novartis and Genentech Sue Over Drug Importation
- Drug Import Lawsuit: Novartis and Genentech have filed a lawsuit against a U.S. company and a Canadian pharmacy for the illegal importation of the allergy medication Xolair, which poses potential risks to patient safety, seeking a court order to halt this practice.
- FDA Regulatory Violations: The lawsuit claims that this importation violates U.S. Food and Drug Administration regulations, as biological medicines like Xolair are highly sensitive to storage and handling conditions, which could lead to contamination and reduced efficacy.
- Rise of Alternative Funding Programs: A CNBC investigation reveals a growing number of alternative funding programs in the U.S., despite federal officials warning that such imports are illegal and could jeopardize patient health.
- Patient Safety Risks: The lawsuit underscores that importing unapproved medications can result in serious patient injuries or even death, with Novartis and Genentech aiming to protect patients from these potential health threats.
See More
Novartis and Genentech Sue Over Illegal Drug Import Scheme
- Illegal Drug Importation: Novartis and Genentech have filed a lawsuit against SHARx and a Canadian pharmacy for allegedly violating FDA regulations by illegally importing the allergy medication Xolair from Canada to the U.S., posing potential health risks to patients.
- Legal Action Context: The lawsuit, filed on February 2 in the U.S. District Court in Michigan, seeks to halt the importation of the drug, emphasizing the sensitivity of biological medicines to storage and handling conditions, which could lead to contamination and degradation.
- Patient Safety Risks: The complaint highlights that importing unapproved drugs can result in serious patient injuries or even death, stressing the strict temperature control requirements during drug transport, thereby underscoring the dangers of such practices.
- Market Regulation Challenges: This case reflects the growing legal gray area surrounding alternative funding programs (AFPs) in drug access, with federal authorities warning about the illegality of such imports, which could threaten patient health.
See More
Gilead Executive Highlights Potential $20 Billion Market for Anti-Cel in First-Line Multiple Myeloma Treatment at TD Cowen Conference
Potential Financial Impact: Sanito-Cel could potentially add up to $20 billion in value through its multiple myeloma treatment options.
Focus on First-Line Treatment: The emphasis is on the use of Sanito-Cel in first-line treatment settings, highlighting its significance in addressing this type of cancer.
See More
Gilead Foundation Invests $12 Million to Strengthen HIV Prevention Efforts
- Investment Scale: Gilead Foundation announced a $12 million investment in 33 community organizations nationwide to support its Community Health Worker Comprehensive HIV Prevention Initiative, aiming to enhance the accessibility and effectiveness of HIV prevention services over the next two years.
- Community Impact: The initiative prioritizes communities most affected by HIV, including Black and Latino men, transgender women, and youth, aiming to reduce health disparities by providing tailored education and prevention services.
- Organizational Infrastructure: Funded organizations will strengthen training systems for community health workers and build sustainable HIV prevention networks, thereby enhancing community trust and engagement in health services.
- Long-term Vision: Gilead Sciences plans to invest $32 billion by 2025 to further strengthen its U.S. operations, driving public health preparedness and scientific innovation to ensure patients worldwide benefit from its medical breakthroughs.
See More
Gilead Executive Anticipates Anti-Cel Launch by Year-End at TD Cowen Conference
- Launch Announcement: The Sanito-Cel is expected to launch by the end of this year, as stated by Gilead executives.
- Event Context: This announcement was made during the TD Cowen conference, highlighting the company's strategic plans.
See More
Significant Milestones in Biotech Sector This Week
- FDA Drug Approvals: Armata Pharmaceuticals' AP-SA02 received FDA's QIDP designation, granting five years of market exclusivity and paving the way for a Phase 3 trial in 2026, which is expected to significantly enhance the company's competitive edge in the antibiotic market.
- Weight Loss Innovation: Allurion Technologies' gastric balloon system gained FDA approval, offering a non-surgical weight loss option for patients with a BMI of 30-40, which is anticipated to expand the company's market share in the obesity sector.
- Acquisition Deal: Gilead Sciences is acquiring Arcellx for $115 per share, totaling $7.8 billion, a move that will strengthen Gilead's position in cell therapy and enhance its collaboration with Kite Pharma.
- Clinical Trial Developments: Novo Nordisk's CagriSema missed key goals in its trial against Zepbound, although it demonstrated a favorable safety profile, which may influence future market strategies.
See More
Novartis and Genentech Sue Over Drug Importation
- Drug Import Lawsuit: Novartis and Genentech have filed a lawsuit against a U.S. company and a Canadian pharmacy for the illegal importation of the allergy medication Xolair, which poses potential risks to patient safety, seeking a court order to halt this practice.
- FDA Regulatory Violations: The lawsuit claims that this importation violates U.S. Food and Drug Administration regulations, as biological medicines like Xolair are highly sensitive to storage and handling conditions, which could lead to contamination and reduced efficacy.
- Rise of Alternative Funding Programs: A CNBC investigation reveals a growing number of alternative funding programs in the U.S., despite federal officials warning that such imports are illegal and could jeopardize patient health.
- Patient Safety Risks: The lawsuit underscores that importing unapproved medications can result in serious patient injuries or even death, with Novartis and Genentech aiming to protect patients from these potential health threats.
See More
Novartis and Genentech Sue Over Illegal Drug Import Scheme
- Illegal Drug Importation: Novartis and Genentech have filed a lawsuit against SHARx and a Canadian pharmacy for allegedly violating FDA regulations by illegally importing the allergy medication Xolair from Canada to the U.S., posing potential health risks to patients.
- Legal Action Context: The lawsuit, filed on February 2 in the U.S. District Court in Michigan, seeks to halt the importation of the drug, emphasizing the sensitivity of biological medicines to storage and handling conditions, which could lead to contamination and degradation.
- Patient Safety Risks: The complaint highlights that importing unapproved drugs can result in serious patient injuries or even death, stressing the strict temperature control requirements during drug transport, thereby underscoring the dangers of such practices.
- Market Regulation Challenges: This case reflects the growing legal gray area surrounding alternative funding programs (AFPs) in drug access, with federal authorities warning about the illegality of such imports, which could threaten patient health.
See More
